Cortexyme announces european screening now underway in the phase 2/3 gain trial

Cortexyme, inc. announced the start of screening in europe for the gain (gingipain inhibitor for treatment of alzheimer’s disease) trial, the company’s ongoing phase 2/3 clinical study of lead investigational medicine cor388 in subjects with mild to moderate alzheimer’s disease (ad). the international trial has been enrolling in the united states since the second quarter of 2019 and is targeting enrollment of approximately 570 subjects. the gain trial is based on the growing body of scienti?c evidence that the bacterium most commonly associated with chronic periodontal disease, porphyromonas gingivalis plays a key role in the development of ad, given its identification in the brains of ad patients and ability to cause neurodegeneration, inflammation, and other pathology associated with alzheimer’s in animal models. the trial evaluates the ability of cor388, an investigational medicine designed to inactivate the toxic proteases, or gingipains, released by the bacteria, to stop or slow further damage to brain cells. prior clinical studies of cor388 showed the compound was well-tolerated and identified positive trends across biomarkers and cognitive tests in subjects with ad.
QNCX Ratings Summary
QNCX Quant Ranking